<sup>68</sup>
            Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

Farolfi, Andrea; Gafita, Andrei; Calais, Jérémie; Eiber, Matthias; Afshar‐Oromieh, Ali; Spohn, Fabian; Barbato, Francesco; Weber, Manuel; Ilhan, Harun; Cervati, Veronica; Wetter, Axel; Hadaschik, Boris; Briganti, Alberto; Walz, Jochen; Pianori, Davide; Fanti, Stefano; Haberkorn, Uwe; Herrmann, Ken; Fendler, Wolfgang P.

doi:10.1097/ju.0000000000000417

Cited by 38 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PET post-SLND in these 16 patients demonstrated the following: 10 (63%) had at least one lesion already detected pre-SLND (PET persistence or mixed) whereas 4 (25%) had new lesions post-SLND only (PET recurrence) (Fig. 3) As demonstrated previously, PSMA-PET outside the prostate bed was highly reproducible and predictive for prostate cancer location (4,15). However, pre-and post-salvage surgery PSMA-PET underestimated the total number of diseased nodes pre-SLND (17).…”

Section: Pre-and Post-surgery Pet Comparisonsupporting

confidence: 63%

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

et al. 2019

Self Cite

View full text Add to dashboard Cite

Introduction: The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with PSA persistence following salvage lymph node dissection (SLND) and pre/post procedure prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET). Material and Methods: 16 patients were included in this multicenter study. Inclusion criteria were: a) PSMA-PET performed for biochemical recurrence before SLND (pre-SLND PET) and b) repeat PSMA-PET performed for persistently elevated PSA level (≥0.1 ng/mL) ≥6 weeks after SLND (post-SLND PET). Image analysis was performed by three independent nuclear medicine physicians applying the molecular imaging TNM system PROMISE. Lesions were confirmed by histopathology, presence on correlative CT/MRI/bone scan or PSA response after focal therapy. Results: post-SLND PET identified PCa-lesions in 88% (14/16) of patients with PSA persistence after SLND. Median PSA was 1.2 ng/mL (IQR, 0.6-2.8 ng/mL). Disease was confined to the pelvis in 56% of patients (9/16) and most of these men had common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%). Extrapelvic disease was detected in 31% of patients (5/16). In pre-and post-SLND PET comparison, 10/16 had at least one lesion already detected at baseline (63% PET persistence); 4/16 had new lesions only (25% PET recurrence); 2 had no disease on post-SLND PET. All validated regions (11 regions in 9 patients) were true positive. 9/14 (64%) patients underwent repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery). Conclusions: SLND of pelvic nodal metastases was often not complete according to PSMA-PET. About two thirds of patients had PET positive nodal disease after SLND already seen on pre-SLND PSMA-PET. Notably, about one quarter of patients had new lesions, not detected by presurgical PSMA-PET.

show abstract

Section: Pre-and Post-surgery Pet Comparisonsupporting

confidence: 63%

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…A significant proportion of liver metastases may also lack PSMA expression, although most liver metastases highly overexpress PSMA [ 76 ]. Heterogeneity of PSMA expression may partly explain why about 30% of patients do not respond to 177 Lu-PSMA RLT [ 77 ]. In contrast, low PSMA expression in patients with mCRPC who progress after conventional therapies may be a negative prognostic indicator [ 78 ].…”

Section: Psma Radioligand Therapy (Rlt)mentioning

confidence: 99%

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Jones

Griffiths

Barata

et al. 2020

Cancers

103

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation in the past two decades as a promising molecular target for prostate cancer (PCa). Its appealing molecular features have enabled the development of a novel diagnostic and therapeutic—thus “theranostic”—approach to PCa. There is now substantial evidence of the high sensitivity of PSMA-targeted imaging for PCa lesions and growing evidence of the therapeutic efficacy of PSMA radioligand therapy for metastatic castration-resistant prostate cancer. This article presents a broad overview of the current status of PSMA theranostics, including current evidence, potential clinical impact, and active areas of research.

show abstract

“…Multiple studies have con rmed a high detection rate of recurrent PCa with various PSMA-targeting radiotracers even in biochemical recurrence patients with low PSA levels, and usually exceeds mpMRI (27)(28)(29). Some studies suggest a strong correlation between PSA levels and diagnostic performance of PSMA-targeting PET tracers (27)(28)(29)(30)(31). Our small sample size cohort did not allow for such a correlation, however in a future study with a larger cohort, imaging results should be correlated with PSA levels to test whether this holds true in patients who have undergone brachytherapy.…”

Section: Discussionmentioning

confidence: 99%

Multiparametric MRI and 18F-DCFPyL PET/CT for Detection of Locally Recurrent Prostate Cancer After Low dose Rate Brachytherapy

Walker¹,

Fernandez²,

Roy³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and purpose: Both multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen (PSMA)-targeting positron emission tomography (PET) imaging have shown promise in early localization of prostate cancer (PCa) recurrence after primary external beam radiotherapy. Detecting recurrence after brachytherapy for PCa using MRI is significantly hampered by susceptibility artifacts secondary to brachy seeds. Here, we compare the efficacy of 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET/CT versus mpMRI for detecting sites of local recurrence after low dose rate (LDR) brachytherapy for prostate cancer. Materials and methods: A total of 155 patients with a history of recurrent PCa who underwent mpMRI at 3 Tesla and 18F-DCFPyL PET/CT were retrospectively reviewed. Patients who underwent LDR brachytherapy for PCa and had subsequent biochemical recurrence (BCR) followed by mpMRI and 18F-DCFPyL PET/CT were included in this study. mpMRI was performed on a 3T scanner with endorectal and surface coils and images were prospectively read by a single expert radiologist. The 18F-DCFPyL PET/CT scan was prospectively interpreted by one of two nuclear medicine physicians. Patients underwent targeted biopsy when deemed clinically necessary and specimens were interpreted by an expert GU pathologist. Positivity rates (PR) from mpMRI and 18F-DCFPyL PET/CT were compared, and pathology results were used to calculate the positive predictive value (PPV) of each imaging modality for detecting PCa recurrence.Results: 14 patients who underwent LDR brachytherapy and had subsequent biochemical failure were imaged with mpMRI and 18F-DCFPyL PET/CT. 17 lesions were identified on at least one imaging modality. The PR for detection of intraprostatic lesions was 71% (10/14) for PET/CT and 64.3% (9/14) for mpMRI. 18F-DCFPyL PET/CT identified pelvic and extra-pelvic lymph nodes in 8 (57%) patients, while mpMRI noted positive lymph node findings in only 2 (14%) patients. A total of 14 lesions corresponding to 8 patients were targeted for biopsy and in these, 18F-DCFPyL PET/CT performed better than mpMRI for the detection of local recurrence with a PPV of 81.8% vs. 66.7%. For the detection of intraprostatic lesions, 18F-DCFPyL PET/CT and mpMRI had a PPV of 87.5% and 71.4%, respectively. Conclusion: Our findings suggest that 18F-DCFPyL PET/CT detects local and regional recurrent PCa after LDR brachytherapy at a higher rate than mpMRI and has a much higher detection rate of suspicious pelvic lymph nodes. Further studies are needed to validate these findings in larger cohorts.

show abstract

⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

Cited by 38 publications

References 0 publications

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Multiparametric MRI and 18F-DCFPyL PET/CT for Detection of Locally Recurrent Prostate Cancer After Low dose Rate Brachytherapy

Contact Info

Product

Resources

About

68 Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study

Cited by 38 publications

References 0 publications

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Multiparametric MRI and 18F-DCFPyL PET/CT for Detection of Locally Recurrent Prostate Cancer After Low dose Rate Brachytherapy

Contact Info

Product

Resources

About

⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study